Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report

Abstract

Pyoderma gangrenosum (PG) is a rare inflammatory skin disease that manifests as painful ulcers (1, 2). While the pathogenesis of PG is not fully understood, it is thought to be related to immune dysfunction, presenting as neutrophil dysfunction, keratinocyte apoptosis, and inappropriate inflammatory responses (3). PG has been reported in patients with a history of certain immune checkpoint inhibitors (4–6). We report here a case of PG that occurred following treatment with concomitant atezolizumab and bevacizumab and was stabilized with a Janus kinase (JAK) inhibitor.